Alcohol Use Disorder
Conditions
Brief summary
The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice. Moreover, other experimental studies have found that CBD reduced alcohol-induced steatosis in the liver, and reduced alcohol-related injury in the brain. Despite these promising results from animal data, no human study has been conducted yet in alcohol use disorder (AUD).
Detailed description
CBD has several potential therapeutic prospects in AUD. Preclinical studies now support the potential of CBD for drinking reduction in AUD subjects. Moreover, other experimental studies have found that CBD reverse the alcohol-induced steatosis process in the liver. These two experimental effects need a translational confirmation in humans through an explanatory phase 2 study. In addition, CBD could also exert neuroprotective effects that reduce the deleterious effects of alcohol on the brain. In both the liver and the brain, the idiosyncratic anti-inflammatory effects of CBD could thus strengthen the overall harm reduction allowed by drinking reduction in AUD ± ALD patients. CBD deserves an exploratory study assessing whether the different therapeutic prospects in AUD are warranted. Moreover, because CBD is extracted from cannabis, and even if it is a CB1 antagonist with no psychotomimetic effects and no reported potential for abuse, the first pieces of evidence in AUD should confirm that CBD is safe in AUD subjects. The CARAMEL study is a phase-2 clinical trial on 76 subjects, which aims to investigate the efficacy of CBD on reducing alcohol drinking, as well as the potential of CBD for restraining alcohol-induced brain and liver injuries, and confirm the good safety profile of CBD.
Interventions
DRUGCannabidiol oral oil
The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
DRUGPlacebo oral oil
Placebo of similar cannabidiol galenic form
Sponsors
Hôpital le Vinatier
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
CLEAVER LEAVES - ECOMEDICS SAS produce Oral oil of Cannabidiol and Placebo of similar galenic form. They will be responsible for the pharmaceutical analyses of the product. Eurofins-LC2 will import the oral oil after authorization from the ANSM, and will relabeled individual vials for each participant, and regular dispatching into the hospital pharmacy. Local hospital pharmacies will be in charge to deliver treatment individual vials to the investigators for dispensing.
Intervention model description
CARAMEL is a phase-2, national, multi-site, interventional (category 1), double-blind, randomized, placebo-controlled trial, conducted in 76 subjects.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Being aged 18 - 65 years * Being fluent in French * Having read the information procedure and signed the informed consent sheet. * Being affiliated with health insurance. * DSM-5 criteria for AUD (all stages) (American Psychiatric Association, 2013) * Average drinking level of at least 12 standard-drinks (120g of ethanol) per day over the month prior to inclusion (i.e., a total alcohol consumption of 336 standard-drinks during the 28-day assessment period prior to inclusion), using the A-TLFB.
Exclusion criteria
* At least one day of abstinence (no alcohol drinking) during the month prior to inclusion * Criteria for liver cirrhosis (Child-Pugh B or C) * DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder, using the MINI 7.0.2. * Current suicidality, using the MNI 7.0.2 * Lifelong history of suicide attempts * Lifelong history or current DSM-5 criteria for substance use disorder (other than alcohol or nicotine) using the MINI 7.0.2. * Any detected use of cannabis or any other cannabinoid within 60 days prior to screen * Patients with transaminase elevations greater than 3 times upper the limit of normal and bilirubin greater than 2 times upper the limit of normal. * Impaired medical condition (investigator's decision) * Pregnancy, lactation, or insufficient contraceptive measure (precautionary measure) (See 5.2 for acceptable birth control methods) * Patients with cancer, HIV, pulmonary arterial hypertension, epilepsy and with rifampicin, St. John's wort, Mammalian target of rapamycin (mTOR), calcineurin inhibitors or triazole antifungal agents like posaconazole, fluconazole… . * History of vascular accident and/or cardiac arrhythmias and/or myocardial infarction * Patients receiving acamprosate, naltrexone, disulfiram, nalmefene, topiramate, baclofen for AUD within 30 days prior to screening. * MRI contraindication: pacemaker, insulin pump, heart metal valve, cochlear implant… * Known hypersensitivity to the active principle (cannabidiol) or excipients (sucralose, menthol, mannitol). * Person under tutorship or curatorship.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the total consumption of alcohol (in standard-drinks, sd) in the 28 last days (week 8 to week 12) of the study, using the Alcohol Timeline Followback (A-TLFB) daily self-report of alcohol drinking | Five months | The difference between the total alcohol consumption during 28 days preceding the study, and the 28 last days of the study, will be compared between the two groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference (i.e., inclusion minus end of study) in alcohol craving scores using the Obsessive Compulsive Drinking Scale (OCDS). | Five months | Inclusion minus end of study using the OCDS. The Obsessive Compulsive Drinking Scale (OCDS) is a 14-item questionnaire that measures an individual's alcohol use and his/her attempts to control his/her drinking. Each item is scored on a scale from 0 to 4.Obsessive subscale is the summation of items 1-6.Compulsive subscale is the summation of items 7-14. |
| Difference in alcohol use disorder scores using the Alcohol Use Disorders Identification Test scale (AUDIT-C). | Five months | inclusion minus end of study The Alcohol Use Disorders Identification Test (AUDIT-C) is an alcohol screen that can help identify patients who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). Probable misuse: score \> 4 for men and \> 3 for women. Probable dependence: score \> 10 regardless of sex. |
| Difference in anxiety and depression Hospital Anxiety and Depression Scale (HADS) | Five months | Inclusion minus end of study Each answer corresponds to a number. By adding these numbers, we obtain a total score per column (anxiety and depression). If the score of a column is greater than or equal to 11, it means that the subject suffers from anxiety or depression |
| Difference in Controlled Attenuation Parameter (CAP) scores | Five months | Inclusion minus end of study Using ultra-sound electrography which measures liver steatosis using transient ultra-sound elastography, between V0 and V4 |
| Change in steatosis scores between V0 and V4, using Proton Density Fat Fraction (PDFF) estimated on the structural liver based on Chemical Shift Encoding-MRI (CSE-MRI) and MR Spectroscopy (MRS). | Five months | Inclusion minus end of study |
| Between-group comparison of recovery of grey matter integrity in corticostriatal-limbic circuits, between V0 and V4, using MRI Voxel Based Morphometry (VBM) and cortical thickness measures. | Five months | Inclusion minus end of study |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORBenjamin ROLLAND, MD, PhD
Centre Hospitalier le Vinatier
Outcome results
None listed